The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2015Orexin Receptor Modulators for the Treatment of Circadian Sleep-wake Disorders in Parkinson's Disease
Study Rationale:
Reset Therapeutics, Inc. (Reset) will develop a new therapy to address excessive daytime sleepiness, a common non-motor symptom in Parkinson’s disease (PD). The natural daily rhythm of... -
Access to Data and Biospecimens, 201514-3-3 Phosphorylation as a Biomarker of Parkinson’s Disease Supplement
Study Rationale:
Disruption of 14-3-3s protein is implicated in Parkinson’s disease (PD). Recently, we observed that 14-3-3 phosphorylation — a chemical modification of 14-3-3s — is... -
Target Validation, 2015Anti-inflammatory Role of Activin-A in Protection against Alpha-synuclein-mediated Pathology
Objective/Rationale:
Neuroinflammation is essential for the pathogenesis and progressionof Parkinson’s disease (PD); therefore, the identification of immunosuppressive agents that can... -
Improved Biomarkers and Clinical Outcome Measures, 2015Eye Tracking as a Biomarker for Manifest and Prodromal Parkinson’s Disease
Study Rationale:
Over the past 14 years, we have utilized sophisticated commercial eye movement monitoring equipment to collect data from over 3300 participants. Our work aims to... -
Therapeutic Pipeline Program, 2015Alpha4Beta2 Nicotinic Agonist for Treatment of L-Dopa Refractory Gait and Balance Disorders in Parkinson Disease
Study Rationale:
Gait and balance problems, particularly falls, are common and disabling symptoms in Parkinson disease (PD), and do not improve markedly with existing treatments. Studies have indicated... -
Target Validation, 2015Validating the Neuroprotective Enzyme ACMSD as a Novel Therapeutic Target in Parkinson's Disease by Viral Vector-Mediated Overexpression
Study Rationale:
A number of genetic studies have linked variation in the enzyme aminocarboxy-muconate semialdehyde decarboxylase (ACMSD) with a risk for Parkinson’s...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.